Lilly notes cost-effectiveness of Effient

Lilly has said a sub-study of the TRITON-TIMI 38 clinical trial has shown the cost-effectiveness of its Effient therapy when compared to Clopidogrel in people with acute coronary syndromes who are undergoing percutaneous coronary intervention.

In a statement, the pharmaceutical firm explained that the research, which was published in the journal Circulation yesterday (January 5th), showed that the drug reduced hospitalisation costs over a period of around 15 months.

Dr David Cohen, director of cardiovascular research at Saint Luke’s Mid-America Heart Institute and professor of medicine at the University of Missouri-Kansas City, said that the study offered “favourable” results.

“Results of the cost-effectiveness analysis showed that treatment with Effient was highly cost-effective and an economically dominant option compared with Plavix,” he added.

In recent days, the company announced that Derica Rice, senior vice-president and chief financial officer at the firm, has taken on new responsibilities and is now executive vice-president of global services and its chief financial officer.